This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.0 | Synonyms: Fanconi anemia (FA), congenital pancytopenia, Constitutional aplastic anaemia with malformations
Pancytopenia with malformations, that is, Fanconi anemia, was first described as an independent disease entity when the Swiss pediatrician Guido Fanconi in 1927 reported 3 brothers with pancytopenia, congenital malformations, and skin pigmentation. The disease was later named Fanconi anemia (FA) after its reporter.
In 1967, Schroeder et al. discovered chromosomal instability in patients with Fanconi anemia, which became both a diagnostic feature of the disease and key to understanding its pathogenesis. Around the same time, chromosomal fragility testing with DNA crosslinking agents such as diepoxybutane (DEB) or mitomycin C (MMC) was established as a diagnostic test.
Since the FANCA gene was first identified in 1992, 22 or more Fanconi anemia complementation group genes (FANCA–FANCW) have been identified to date. Their gene products constitute the FA/BRCA DNA damage repair pathway and play an essential role in the repair of DNA crosslink damage. Defects in this pathway have been shown to be the common pathogenesis of pancytopenia, congenital malformations, and susceptibility to malignancy.
In Korea, patients with Fanconi anemia have been included in the rare disease registration system since the 1990s. Korean studies have reported that most Korean patients have FANCA, FANCC, or FANCG variants, and outcomes of hematopoietic stem cell transplantation have also been improving.
The cause of pancytopenia with malformations (Fanconi anemia) is biallelic loss-of-function variants in 22 or more genes involved in the FA/BRCA DNA damage repair pathway. FANCA variants are the most common, accounting for about 60–70% of all Fanconi anemia patients, followed by FANCC (about 14%) and FANCG (about 10%).
| Gene | Complementation group | Frequency (%) | Notes |
|---|---|---|---|
| FANCA | A | About 60–70% | Most common cause, various deletion variants |
| FANCC | C | About 14% | Ashkenazi Jewish founder variant |
| FANCG | G | About 10% | Relatively high frequency in Asians |
| FANCD2 | D2 | About 3% | Key monoubiquitination target |
| FANCD1/BRCA2 | D1 | About 2% | Early onset, high risk of solid tumors |
Patients with biallelic FANCD1 (BRCA2) variants develop bone marrow failure early and have a very high risk of solid tumors (medulloblastoma, Wilms tumor, brain tumors). Monoallelic BRCA2 variants are associated with familial breast/ovarian cancer. In Koreans, FANCA, FANCC, and FANCG variants are mainly reported.
Most Fanconi anemia follows an autosomal recessive inheritance pattern. Cases due to FANCB variants show X-linked recessive inheritance. Carriers are present in the general population at a frequency of 1/200–1/300, and the incidence increases in populations with high rates of consanguineous marriage.
The gene products of all 22 complementation groups interact in the FA/BRCA pathway. The core complex (FANCA, B, C, E, F, G, L, M, T) monoubiquitinates the FANCD2/FANCI proteins at DNA crosslink sites, activating downstream repair proteins (FANCD1/BRCA2, FANCN/PALB2, FANCJ/BRIP1, etc.).
In some Fanconi anemia patients, mosaicism due to spontaneous somatic reversion in hematopoietic cells is observed. This can lessen clinical symptoms but can also cause selective expansion of cell clones at risk of leukemia, so when somatic mosaicism is suspected, confirmatory testing should be performed with skin fibroblasts.
The incidence of Fanconi anemia is estimated at about 1–5 per million births. About 2,000 patients are registered worldwide, but actual occurrence is presumed to be higher. The carrier frequency is estimated at 1/200–1/300. Increased incidence due to founder variants has been confirmed in specific populations such as Ashkenazi Jews and people of Spanish descent.
Bone marrow failure (pancytopenia) usually appears between ages 5 and 10, with a median age of onset of about 7 years. Congenital malformations are found at birth or in infancy, and malignancies (head and neck squamous cell carcinoma, AML) occur mainly in adulthood. In the early-onset type (FANCD1 variants), bone marrow failure and solid tumors develop within months to years after birth.
In Korea, Fanconi anemia is listed in the rare disease registry program, and according to Health Insurance Review & Assessment Service (HIRA) data, about 10–30 new patients are registered annually. Several tertiary medical institutions in Korea follow patient cohorts, and outcomes of hematopoietic stem cell transplantation are continually improving.
The core pathogenesis of Fanconi anemia is inability to repair DNA interstrand crosslink (ICL) damage due to defects in the FA/BRCA pathway. In normal cells, when the DNA replication fork reaches an ICL, the FA core complex monoubiquitinates FANCD2/FANCI and recruits nucleases (SLX4/XPF), translesion synthesis polymerases, and homologous recombination (BRCA2, RAD51, PALB2) proteins to repair the ICL.
When ICLs cannot be repaired because of FA pathway defects, replication fork collapse, DNA double-strand breaks (DSBs), and chromosome breakage and rearrangement occur. Hematopoietic progenitor cells (HSCs) are particularly vulnerable because, with their high replication rate, they are continuously exposed to endogenous crosslinking agents such as endogenous formaldehyde and acetaldehyde. Over time, hematopoietic progenitor cells are depleted and pancytopenia develops.
The FA pathway is also active during fetal development. Malformations are presumed to arise from defective ICL damage repair in rapidly proliferating cell populations during fetal development (limb buds, renal development, etc.). Genomic instability due to FA pathway defects greatly increases the risk of AML, MDS, and solid tumors (head and neck squamous cell carcinoma, esophageal cancer, etc.).
About 60–70% of Fanconi anemia patients have various congenital malformations. The most common malformations are thumb/radial anomalies (thumb hypoplasia, absent thumb, triphalangeal thumb, absent radius, etc.); other reported anomalies include skin hypopigmentation or hyperpigmentation (café-au-lait spots), renal anomalies (horseshoe kidney), microcephaly, short stature, microphthalmia, external ear anomalies, cardiac anomalies, and genital anomalies.
Pancytopenia presents as anemia (pallor, fatigue, dyspnea), leukopenia (recurrent infections, fever), and thrombocytopenia (bleeding tendency, bruising, gum bleeding, petechiae). In most cases it appears gradually after ages 5–10, but in some it occurs in infancy. In patients with FANCD1 (BRCA2) variants, pediatric solid tumors (medulloblastoma, Wilms tumor, retinoblastoma) also occur.
Patients with Fanconi anemia have a risk of head and neck squamous cell carcinoma, esophageal cancer, vulvar cancer, and anal cancer hundreds of times higher than the general population. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are also major complications and, together with head and neck cancer occurring in adulthood, threaten the long-term survival of patients with Fanconi anemia.
On physical examination, café-au-lait spots, generalized hypopigmented macules, thumb/radial anomalies, microcephaly, and microphthalmia may be observed. Pallor due to anemia and petechiae, purpura, and bruising due to thrombocytopenia appear. Short stature is related to growth disorders and endocrine abnormalities. Hepatosplenomegaly may be related to extramedullary hematopoiesis or hepatic complications.
A complete blood count characteristically shows pancytopenia (anemia, leukopenia, thrombocytopenia). The anemia is often macrocytic and accompanied by elevated HbF. Reticulocytopenia, absolute neutrophil count (ANC) < 1,000/μL, platelets < 50,000/μL, and similar findings are typical. Bone marrow examination shows reduced cellularity (hypocellular marrow), fatty replacement, and reduced residual hematopoietic cells.
Increased chromosome breaks, radial chromosomes, and exchanges after treatment with DEB (diepoxybutane) or MMC (mitomycin C) are the diagnostic markers of Fanconi anemia. When somatic mosaicism is present, testing should be done on skin fibroblast samples rather than peripheral blood to avoid false negatives.
When cytopenia is found in a child with congenital malformations (thumb anomalies, café-au-lait spots, etc.), Fanconi anemia is suspected and a DEB/MMC test is performed. Conversely, when congenital malformations accompany pancytopenia or aplastic anemia, Fanconi anemia must be differentiated.
Siblings of confirmed patients are screened with the DEB/MMC test. Carrier status is confirmed by molecular genetic testing, and in particular carriers of FANCB/BRCA2, FANCN/PALB2, and FANCS/BRCA1 need surveillance for increased risk of breast and ovarian cancer. Prenatal diagnosis (CVS, amniocentesis) and PGT-M can also prevent implantation of affected embryos.
The gold-standard diagnostic test is the chromosome breakage test using DEB (diepoxybutane) or MMC (mitomycin C). Because of defective DNA crosslink repair in Fanconi anemia cells, chromosome breaks, radial figures, and exchanges after DEB/MMC treatment are markedly increased compared with normal cells. When somatic mosaicism is suspected, skin fibroblasts are used.
The causative gene variants are identified with an FA gene panel (22 or more genes) or whole-exome sequencing (WES). Some large deletions are confirmed with MLPA. Gene identification is essential for FA complementation group classification, prognosis prediction, family counseling, and selection of hematopoietic stem cell transplant donors.
Bone marrow aspiration and biopsy assess hematopoietic cellularity, dysplasia, and cytogenetic abnormalities (in particular, 1q+ or 3q26q29 abnormalities predict the risk of progression to AML). Bone marrow cytogenetic testing is performed regularly and used for early detection of MDS/AML.
Androgens (especially oxymetholone or danazol) partially improve pancytopenia through a hematopoiesis-stimulating effect. The response rate is about 50–60%, and improvement in blood counts appears within a few months of starting treatment. Major adverse effects include virilization, hepatotoxicity (hepatic adenoma, liver cancer), and reduced height due to premature closure of growth plates. Androgen therapy is used as a bridge to HSCT.
HSCT from an HLA-matched sibling donor is the only curative treatment. Because FA patients are highly sensitive to radiation and alkylating agents, reduced-intensity conditioning (RIC) is essential, and fludarabine-based RIC is used. Long-term survival after HLA-matched sibling donor HSCT reaches about 70–90%. Outcomes of unrelated donor or haploidentical transplantation are also gradually improving.
Regular endoscopic and imaging surveillance for the development of solid tumors such as head and neck squamous cell carcinoma is needed. In FA patients, radiation and some chemotherapeutic agents (alkylating agents, platinum compounds) cause serious toxicity, so dose adjustment is essential when treating tumors.
The median age of survival of untreated Fanconi anemia patients is about 16–20 years. The main causes of death are bone marrow failure (infection, bleeding), AML/MDS, and solid tumors (head and neck cancer). Hematopoietic function recovers after HSCT, but the risk of solid tumors persists, so long-term follow-up is needed even after transplantation.
When fludarabine-based RIC-HSCT is performed from an HLA-matched sibling donor, the 5-year overall survival rate is about 70–90%, a major improvement. Even after HSCT, the risk of solid tumors such as head and neck squamous cell carcinoma persists (about 500–700 times that of the general population).
In patients with Fanconi anemia, the cumulative incidence of head and neck squamous cell carcinoma is reported to be about 30% or more by age 50. Even after HSCT, the risk of head and neck cancer is markedly elevated, and regular endoscopic surveillance is needed.
When Fanconi anemia is confirmed, genetic counseling and screening of parents and siblings are essential. Carrier parents (autosomal recessive form) have a 25% risk with each pregnancy, so prenatal diagnosis is recommended. Carriers of FANCB/BRCA2, FANCN/PALB2, and FANCS/BRCA1 should be enrolled in surveillance programs for increased risk of breast and ovarian cancer.
In Fanconi anemia families, prenatal genetic testing is possible via CVS (10–13 weeks of gestation) or amniocentesis (15–20 weeks of gestation). With in vitro fertilization, implantation of affected embryos can be prevented with PGT-M, or a savior sibling can be selected to serve as an HLA-matched HSCT donor.
Blood counts 1–2 times a year to monitor declining bone marrow function, annual bone marrow examination and cytogenetic analysis for early detection of MDS/AML, and annual endoscopy for surveillance of head and neck squamous cell carcinoma are recommended. Alcohol and smoking must be prohibited because they further increase the risk of head and neck cancer.